menu
    • menu
    [{"orgOrder":0,"company":"Rubedo Life Sciences","sponsor":"Khosla Ventures","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Discovery Platform","graph3":"Rubedo Life Sciences","amount2":0.01,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"Rubedo Life Sciences \/ Khosla Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Rubedo Life Sciences \/ Khosla Ventures"},{"orgOrder":0,"company":"Rubedo Life Sciences","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"RBO-0618","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Discovery","graph3":"Rubedo Life Sciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Rubedo Life Sciences \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"2","companyTruncated":"Rubedo Life Sciences \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"Rubedo Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Rubedo Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Rubedo Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Rubedo Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Rubedo Life Sciences","sponsor":"Khosla Ventures","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Series A Financing","leadProduct":"RLS-1496","moa":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Rubedo Life Sciences","amount2":0.040000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Rubedo Life Sciences \/ Khosla Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Rubedo Life Sciences \/ Khosla Ventures"},{"orgOrder":0,"company":"Rubedo Life Sciences","sponsor":"Beiersdorf AG","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Partnership","leadProduct":"RLS-1496","moa":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Rubedo Life Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Rubedo Life Sciences \/ Beiersdorf AG","highestDevelopmentStatusID":"5","companyTruncated":"Rubedo Life Sciences \/ Beiersdorf AG"},{"orgOrder":0,"company":"Rubedo Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"RLS-1496","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Rubedo Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Rubedo Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Rubedo Life Sciences \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Rubedo Life Sciences

    Menu

    Rubedo Life Sciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Rubedo Life Sciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Rubedo Life Sciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RLS-1496

                            Therapeutic Area : Dermatology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Rubedo Life Sciences Announces European Expansion Ahead of First Clinical Trial

                            Details : RLS-1496 is a topically administered therapeutic, and the Phase 1 study will include patients with skin conditions to test safety in primary endpoints.

                            Brand Name : RLS-1496

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 23, 2024

                            Lead Product(s) : RLS-1496

                            Therapeutic Area : Dermatology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Rubedo Life Sciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Rubedo Life Sciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RLS-1496

                            Therapeutic Area : Dermatology

                            Study Phase : IND Enabling

                            Sponsor : Khosla Ventures

                            Deal Size : $40.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Rubedo Closes $40M Series A Financing Led by Khosla Ventures, Ahren Innovation

                            Details : The funding will be utilized to progress the company’s primary candidate, RLS-1496, for treating patients with atopic dermatitis and chronic psoriasis.

                            Brand Name : RLS-1496

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 22, 2024

                            Lead Product(s) : RLS-1496

                            Therapeutic Area : Dermatology

                            Highest Development Status : IND Enabling

                            Sponsor : Khosla Ventures

                            Deal Size : $40.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Rubedo Life Sciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Rubedo Life Sciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RLS-1496

                            Therapeutic Area : Dermatology

                            Study Phase : IND Enabling

                            Sponsor : Beiersdorf AG

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Rubedo Pulls in $40M Series A to Advance Atopic Dermatitis Candidate Targeting Aging Cells

                            Details : The financing will be utilized to fund the progress of the company’s primary candidate, RLS-1496, for treating patients with atopic dermatitis and chronic psoriasis.

                            Brand Name : RLS-1496

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 22, 2024

                            Lead Product(s) : RLS-1496

                            Therapeutic Area : Dermatology

                            Highest Development Status : IND Enabling

                            Sponsor : Beiersdorf AG

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Rubedo Life Sciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Rubedo Life Sciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Dermatology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Rubedo Life Sciences Presents In Vivo Efficacy Data Targeting Senescence Cells to Treat Dermatological Disease...

                            Details : Presented in vivo efficacy data for its small molecule therapy engineered via ALEMBIC™ drug discovery platform, targetes senescent cells that drive cellular aging to treat dermatological diseases.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 20, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Dermatology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Rubedo Life Sciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Rubedo Life Sciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RBO-0618

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Discovery

                            Sponsor : California Institute for Regenerative Medicine

                            Deal Size : $1.4 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Rubedo Life Sciences Awarded $1.45M in Funding From the California Institute for Regenerative Medicine (CIRM) ...

                            Details : The funding will support research and development of a pharmacological regenerative treatment of idiopathic pulmonary fibrosis (IPF), RBO-0618, targeting senescent lung stem cells.

                            Brand Name : RBO-0618

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 06, 2023

                            Lead Product(s) : RBO-0618

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Discovery

                            Sponsor : California Institute for Regenerative Medicine

                            Deal Size : $1.4 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Rubedo Life Sciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Rubedo Life Sciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Discovery Platform

                            Sponsor : Khosla Ventures

                            Deal Size : $12.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Rubedo Life Sciences Closes $12M Seed Financing Led by Khosla Ventures

                            Details : The funding will be used to advance the company’s lead candidates in respiratory diseases with significant unmet medical need, such as idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 03, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Discovery Platform

                            Sponsor : Khosla Ventures

                            Deal Size : $12.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth